8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_____________________________________________________________________

FORM 8-K/A

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

______________________________________________________________________

Date of Report (Date of earliest event reported): May 1, 2015

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in charter)

DELAWARE	1-11083	04-2695240
(State or other	(Commission	(IRS employer
jurisdiction of	file number)	identification no.)
incorporation)

300 Boston Scientific Way, Marlborough, Massachusetts	01752-1234
(Address of principal executive offices)	(Zip code)

Registrant's telephone number, including area code:   (508) 683-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. REGULATION FD DISCLOSURE

This Current Report on Form 8-K/A is being filed as an amendment (this “Amendment”) to the Current Report on Form 8-K filed by Boston Scientific Corporation (the “Company”) with the Securities and Exchange Commission on May 1, 2015 (the “Original Filing”). The Investor Presentation attached as Exhibit 99.1 to the Original Filing contained an error on slides 22 and 143 related to organic revenue goals for 2017 and 2018-2019 and an error on slide 133 related to as reported revenue guidance for 2015. The sole purpose of this Amendment is to provide the corrected slides that will be included in the Investor Day presentation to be posted on the Investor Relations section of the Company’s website.

The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this report, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit No.    Description

99.1    Slides 22, 133 and 143 of the Investor Day presentation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOSTON SCIENTIFIC CORPORATION

Date: May 6, 2015By: /s/ Vance R. Brown

Vance R. Brown

Vice President and Chief Corporate Counsel

EX-99.1

Where are we going? Guidance 2015E Goals 2016E Goals 2017E Goals 2018-2019E Organic Revenue +3-5% +3-6% +3-6% +4-7% Operational Revenue +5-8% with AMS & Bayer Int. +5-9% with AMS Upside from potential M&A Adjusted Op. Margin 22.0-22.5% +~150 bps 25%+ +50-100bps annually Adjusted EPS $0.88-0.92 +5%-10% +13%-17% ex FX target double digit growth ex-FX Mid-single digit growth company with differentiated margin expansion, driving double-digit adjusted EPS growth (excluding FX) 22 Exhibit 99.1

2015 Guidance: Continued execution Measure FY 2015 As Reported Revenue ($M) 7,225 to 7,375 Operational Growth +4% to +6% As Reported Growth -2% to flat vs. FY 2014A Adjusted Gross Margin 71% to 72% +30 bps to +130 bps Adjusted SG&A % of Sales 36.5% to 37.5% -140 bps to -40 bps Adjusted R&D % of Sales 11% to 12% -10 bps to +90 bps Adjusted Operating Margin 22.0% to 22.5% +180 bps to +230 bps Adjusted Tax Rate 13% to 15% Adjusted EPS $0.88 to $0.92 GAAP EPS $0.32 to $0.38 133 Exhibit 99.1

Where are we going? Guidance 2015E Goals 2016E Goals 2017E Goals 2018-2019E Organic Revenue +3-5% +3-6% +3-6% +4-7% Operational Revenue +5-8% with AMS & Bayer Int. +5-9% with AMS Upside from potential M&A Adjusted Op. Margin 22.0-22.5% +~150 bps 25%+ +50-100bps annually Adjusted EPS $0.88-0.92 +5%-10% +13%-17% ex FX target double digit growth ex-FX Mid-single digit growth company with differentiated margin expansion, driving double-digit adjusted EPS growth (excluding FX) 143 Exhibit 99.1